<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03170219</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00070619</org_study_id>
    <nct_id>NCT03170219</nct_id>
  </id_info>
  <brief_title>Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study</brief_title>
  <acronym>SUBQ-HF</acronym>
  <official_title>Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adrian Hernandez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if a strategy of early discharge using a novel subcutaneous delivery system for
      parenteral furosemide can improve clinical outcomes within 30 days of randomization (days
      alive and outside the hospital) compared to usual care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SUBQ-HF is a multicenter clinical trial of selected AHF patients with persistent congestion.
      This study will evaluate a strategy of early discharge (pathway 1) or admission avoidance
      (pathway 2) with daily SQ furosemide compared to usual care in a population who have
      objective evidence of persistent congestion requiring ongoing parenteral diuretics. This will
      be an unblinded, randomized, controlled study of approximately 300 evaluable patients.
      Eligible patients will be randomized (1:1) to either:

      Usual care strategy, during which patients will have continued inpatient treatment and
      discharge follow-up as per usual standard of care plus a Day 7 phone call and Day 30 study
      visit.

      or

      Subcutaneous strategy, in which patients will be discharged home within 24 hours of
      randomization (pathway 1) or sent home from clinic or ED to receive furosemide with the SQ
      pump for 1-7 days (based on clinical response) plus a Day 7 and Day 30 visit.

      Subcutaneous furosemide/early discharge strategy:

      Subjects will receive device training and study materials (SQ pump device and up to a 7 day
      supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged
      within 24 hours. Training will include instruction on daily weights and dyspnea numerical
      rating for symptoms. Scales will be provided to subjects. Subjects will be discharged with
      planned treatment of 80 mg SQ furosemide injection over 5-hours either QD or BID, depending
      on anticipated diuretic requirements. If there are unanticipated delays in discharge after
      randomization, subjects will continue with their assigned therapy and assessments in the
      hospital. Discharged subjects will receive a phone contact from study team on D1, D3, and D5
      in order to assess adequacy of diuresis, persistence of congestion, and planned duration,
      dose of ongoing SQ therapy (see Appendix for guidelines on adjusting therapy) and adverse
      events. Additional clinical contact (additional phone contacts or clinical visits) may be
      performed if felt clinically indicated by the study team or clinical provider. All subjects
      will have assessment of electrolytes and renal function by protocol 2 days post discharge.
      More frequent electrolyte monitoring can be performed at the discretion of the study team or
      clinical provider as clinically indicated. Patients receiving the SQ pump for outpatient use
      should be prescribed a supplementation regimen based on electrolyte supplementation needs in
      the hospital with IV diuretic therapy. The duration of subcutaneous therapy will be planned
      for 1-7 days depending on clinical response. Dose and frequency of oral diuretics once SQ
      therapy is completed will be per the discretion of the treating physician.

      Usual care strategy:

      Subjects randomized to usual care will continue to receive inpatient therapy, eventual
      transition to oral diuretics, and discharge and post discharge care as per the discretion of
      the treating clinician and standard treatment guidelines. In addition, they will have a Day 7
      study phone call and a Day 30 study visit.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment
  </why_stopped>
  <start_date type="Actual">April 27, 2018</start_date>
  <completion_date type="Actual">September 20, 2018</completion_date>
  <primary_completion_date type="Actual">September 20, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Safety Measured by Serious Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>measured by serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Safety Endpoint of Death, Sustained Ventricular Arrhythmias, and Severe Hypokalemia</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Costs From Randomization Through 30 Days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Alive and Outside the Hospital Through 14 Days</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 Day Heart Failure Readmission</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 Day ED Visit for Heart Failure</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death at 30 Days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Breathlessness Through Day 7</measure>
    <time_frame>7 days</time_frame>
    <description>On a 0-10 scale of breathlessness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal Function Using eGFR Baseline to 30 Days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT Pro BNP From Baseline to 30 Days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Acute Heart Failure</condition>
  <condition>Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>Subcutaneous Furosemide and sc2wear device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>subcutaneous furosemide and sc2wear device</intervention_name>
    <description>subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
    <arm_group_label>Subcutaneous Furosemide and sc2wear device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Pathway 1 (patients hospitalized with acute heart failure)

          1. Age &gt;18 years

          2. Willingness and ability to provide informed consent

          3. Hospitalization for AHF with at least 1 symptom (dyspnea, orthopnea, or edema) AND 1
             sign (rales on auscultation, peripheral edema, ascites, pulmonary vascular congestion
             on chest radiography, BNP &gt; 250 ng/mL or NTproBNP &gt; 1000 ng/mL) of congestion

          4. Persistent congestion defined by the presence of at least 2 or more of the following
             at the time of consent:

               1. Peripheral edema

               2. Rales

               3. Elevated JVP

               4. Ascites

               5. BNP &gt; 250 ng/mL or NTproBNP &gt; 1000 ng/mL during index hospitalization

               6. Orthopnea

          5. Total anticipated daily IV furosemide dose (at time of screening) &gt;80-240 mg (or
             equivalent)/day

          6. Anticipated need for at least 24 more hours of parenteral diuretic therapy

        Exclusion Criteria for Pathway 1

          1. Severe renal dysfunction (eGFR&lt; 20 ml/min/1.73m2) within 24 hours of enrollment

          2. Requirement for inotropes (other than digoxin) or mechanical support during
             hospitalization

          3. Clinically significant electrical instability during hospitalization

          4. Anticipated need for ongoing intravenous therapies beyond diuretics (electrolyte
             repletion, vasodilators, antibiotics, etc.)

          5. Planned discharge to location other than home (e.g., hospice, skilled nursing
             facility, etc.)

          6. Anticipated cardiac transplantation or left ventricular assist device within the next
             30 days

          7. Primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy, acute myocarditis,
             constrictive pericarditis or tamponade

          8. Known or anticipated pregnancy in the next 30 days

          9. Prior use of a subcutaneous furosemide pump or current use of any subcutaneous pump,
             on-body infusion devices or patients who give regimented injections at the intended
             site of the furosemide infusion device.

         10. Other psychosocial or physical barriers to following the protocol and using SQ pump
             device outside the hospital setting

         11. Known allergy to furosemide

         12. Known sensitivity or allergy to medical adhesive tape

         13. Enrollment or planned enrollment in another therapeutic clinical trial in next 3
             months

         14. Presentation is for indication other than CHF

        Inclusion Criteria for Pathway 2 (Outpatients with heart failure presenting with volume
        overload necessitating treatment with parenteral loop diuretics)

          1. Age &gt;18 years

          2. Willingness and ability to provide informed consent

          3. HF now presenting with volume overload defined by the presence of at least 2 or more
             of the following at the time of consent:

               1. Peripheral edema

               2. Rales

               3. Elevated JVP

               4. Ascites

               5. BNP &gt; 250 ng/mL or NTproBNP &gt; 1000 ng/mL during this episode of decompensation

               6. Orthopnea

          4. Need for parenteral furosemide with an estimated SQ furosemide requirement between
             80-240 mg/day

          5. Anticipated need for at least 24 hours of parenteral diuretic therapy

        Exclusion Criteria for Pathway 2

          1. Severe renal dysfunction (eGFR&lt; 20 ml/min/1.73m2) within 24 hours of enrollment

          2. Anticipated need for inotropes (other than digoxin) or mechanical support to treat
             current episode of decompensation

          3. Clinically significant electrical instability requiring hospitalization

          4. Anticipated need for ongoing intravenous therapies beyond diuretics (electrolyte
             repletion, vasodilators, antibiotics, etc.)

          5. Residence at location other than home (e.g., hospice, skilled nursing facility, etc.)

          6. Anticipated cardiac transplantation or left ventricular assist device within the next
             30 days

          7. Primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy, acute myocarditis,
             constrictive pericarditis or tamponade

          8. Known or anticipated pregnancy in the next 30 days

          9. Prior use of a subcutaneous furosemide pump or current use of any subcutaneous pump,
             on-body infusion devices or patients who give regimented injections at the intended
             site of the furosemide infusion device.

         10. Other psychosocial or physical barriers to following the protocol and using SQ pump
             device outside the hospital setting

         11. Known allergy to furosemide

         12. Known sensitivity or allergy to medical adhesive tape

         13. Enrollment or planned enrollment in another therapeutic clinical trial in next 3
             months.

         14. Presentation is for indication other than CHF.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugene Braunwald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals- Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Health System</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvaina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 6, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <results_first_submitted>November 29, 2018</results_first_submitted>
  <results_first_submitted_qc>January 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2019</results_first_posted>
  <last_update_submitted>January 1, 2019</last_update_submitted>
  <last_update_submitted_qc>January 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Adrian Hernandez</investigator_full_name>
    <investigator_title>HFN Coordinating Center PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03170219/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subcutaneous Furosemide and sc2wear Device</title>
          <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
subcutaneous furosemide and sc2wear device: subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subcutaneous Furosemide and sc2wear Device</title>
          <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
subcutaneous furosemide and sc2wear device: subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="15.2"/>
                    <measurement group_id="B2" value="64.3" spread="6.4"/>
                    <measurement group_id="B3" value="62.2" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Safety Measured by Serious Adverse Events</title>
        <description>measured by serious adverse events</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Furosemide and sc2wear Device</title>
            <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
subcutaneous furosemide and sc2wear device: subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Safety Measured by Serious Adverse Events</title>
          <description>measured by serious adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Safety Endpoint of Death, Sustained Ventricular Arrhythmias, and Severe Hypokalemia</title>
        <time_frame>30 days</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Furosemide and sc2wear Device</title>
            <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
subcutaneous furosemide and sc2wear device: subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Safety Endpoint of Death, Sustained Ventricular Arrhythmias, and Severe Hypokalemia</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Costs From Randomization Through 30 Days</title>
        <time_frame>30 days</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Furosemide and sc2wear Device</title>
            <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
subcutaneous furosemide and sc2wear device: subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Costs From Randomization Through 30 Days</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Alive and Outside the Hospital Through 14 Days</title>
        <time_frame>14 days</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Furosemide and sc2wear Device</title>
            <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
subcutaneous furosemide and sc2wear device: subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Alive and Outside the Hospital Through 14 Days</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30 Day Heart Failure Readmission</title>
        <time_frame>30 days</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Furosemide and sc2wear Device</title>
            <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
subcutaneous furosemide and sc2wear device: subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>30 Day Heart Failure Readmission</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30 Day ED Visit for Heart Failure</title>
        <time_frame>30 days</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Furosemide and sc2wear Device</title>
            <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
subcutaneous furosemide and sc2wear device: subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>30 Day ED Visit for Heart Failure</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death at 30 Days</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Furosemide and sc2wear Device</title>
            <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
subcutaneous furosemide and sc2wear device: subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Death at 30 Days</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Breathlessness Through Day 7</title>
        <description>On a 0-10 scale of breathlessness</description>
        <time_frame>7 days</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Furosemide and sc2wear Device</title>
            <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
subcutaneous furosemide and sc2wear device: subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Breathlessness Through Day 7</title>
          <description>On a 0-10 scale of breathlessness</description>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Renal Function Using eGFR Baseline to 30 Days</title>
        <time_frame>30 days</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Furosemide and sc2wear Device</title>
            <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
subcutaneous furosemide and sc2wear device: subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Renal Function Using eGFR Baseline to 30 Days</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in NT Pro BNP From Baseline to 30 Days</title>
        <time_frame>30 days</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Furosemide and sc2wear Device</title>
            <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
subcutaneous furosemide and sc2wear device: subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in NT Pro BNP From Baseline to 30 Days</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time of consent to day 30</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Subcutaneous Furosemide and sc2wear Device</title>
          <description>Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
subcutaneous furosemide and sc2wear device: subcutaneous furosemide administered via sc2wear device vs. standard of care</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Medra</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transferrin Saturation Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rachel Olson, Project Leader</name_or_title>
      <organization>Duke Clinical Research Institute</organization>
      <phone>919-668-5590</phone>
      <email>rachel.e.olson@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

